High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
暂无分享,去创建一个
G. Ball | I. Ellis | R. Blamey | S. Pinder | J. Robertson | E. Rakha | D. A. Abd El-Rehim | C. Paish | D. Macmillan
[1] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.
[2] H. Høst,et al. Age as a prognostic factor in breast cancer , 1986, Cancer.
[3] I Persson,et al. The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.
[4] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[5] M. Fernö,et al. Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses , 1990 .
[6] M. Fernö,et al. Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group. , 1990, Acta oncologica.
[7] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[8] R. Blamey,et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up , 1992, Histopathology.
[9] S. Pinder,et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.
[10] J Horiguchi,et al. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. , 1995, Anticancer research.
[11] J. Wesseling,et al. Is episialin/MUC1 involved in breast cancer progression? , 1995, Cancer letters.
[12] J. Wesseling,et al. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.
[13] D. Palmer-Brown,et al. Investigating microclimatic influences on ozone injury in clover (Trifolium subterraneum) using artificial neural networks , 1996 .
[14] Dieter Niederacher,et al. Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.
[15] Dihua Yu,et al. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.
[16] Dominic Palmer-Brown,et al. Modeling complex environmental data , 1997, IEEE Trans. Neural Networks.
[17] F. Harrell,et al. Artificial neural networks improve the accuracy of cancer survival prediction , 1997, Cancer.
[18] D. Wynford‐Thomas,et al. Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology. , 1997, European journal of cancer.
[19] N. Kohno,et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.
[20] J. Bonneterre,et al. Age as a prognostic factor in breast cancer. , 1998, Anticancer research.
[21] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[22] Zsolt Tulassay,et al. Application of neural networks in medicine - a review , 1998 .
[23] K Vajda,et al. [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.
[24] R. Moll,et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.
[25] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[26] H Buerger,et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.
[27] I. Ellis,et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers , 1999, International journal of cancer.
[28] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[29] S. Hellman,et al. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. , 2000, Cancer research.
[30] F. Bertucci,et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. , 2000, Human molecular genetics.
[31] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[32] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[33] F. Révillion,et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] H. Olsson,et al. Tumour biology of a breast cancer at least partly reflects the biology of the tissue/epithelial cell of origin at the time of initiation — a hypothesis , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[35] D L Rimm,et al. Amplification of tissue by construction of tissue microarrays. , 2001, Experimental and molecular pathology.
[36] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[37] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. V. van Diest,et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.
[39] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[40] Ash A. Alizadeh,et al. Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.
[41] G. Li,et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers , 2002, Bioinform..
[42] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[43] Martin Eisenacher,et al. Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.
[44] G. Cevenini,et al. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. , 2002, Journal of clinical pathology.
[45] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[46] F. Bertucci,et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.
[47] L. Belghiti,et al. Prognostic factors in breast cancer , 2002 .
[48] Hiroko Yamashita,et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer , 2003, Breast Cancer Research.
[49] L. Bégin,et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma , 2003, Cancer.
[50] Carlos Caldas,et al. Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[51] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[52] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[53] S. Bull,et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[55] Jolanta Lissowska,et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.